Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
1988-4-13
|
| pubmed:abstractText |
Usual treatments of metastatic renal cell carcinoma are not efficient. Phase II trials using Interferon alpha showed a low response rate (10 to 15%). We have conducted a phase I-II trial using a combination of Vinblastine and Recombinant alpha 2 A Interferon in 21 patients. The response rate is of 43% including 1 complete and 8 partial remissions, 5 stabilizations and 8 progressive diseases. In spite of important side effects, these results are promising.
|
| pubmed:language |
fre
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0248-0018
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
93
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
463-6
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:3440838-Adult,
pubmed-meshheading:3440838-Aged,
pubmed-meshheading:3440838-Carcinoma, Renal Cell,
pubmed-meshheading:3440838-Drug Evaluation,
pubmed-meshheading:3440838-Drug Therapy, Combination,
pubmed-meshheading:3440838-Female,
pubmed-meshheading:3440838-Follow-Up Studies,
pubmed-meshheading:3440838-Humans,
pubmed-meshheading:3440838-Interferon Type I,
pubmed-meshheading:3440838-Kidney Neoplasms,
pubmed-meshheading:3440838-Male,
pubmed-meshheading:3440838-Middle Aged,
pubmed-meshheading:3440838-Recombinant Proteins,
pubmed-meshheading:3440838-Vinblastine
|
| pubmed:year |
1987
|
| pubmed:articleTitle |
[Medical treatment of metastatic cancer of the kidney with a combination of vinblastine and recombinant interferon alpha IIa. Result of a phase I-II trial].
|
| pubmed:affiliation |
Service de Chirurgie Urologique, Hôpital de Hautepierre, CHU, Strasbourg.
|
| pubmed:publicationType |
Journal Article,
English Abstract
|